What is COLA?
COLA Inc. operates as a premier physician-directed accrediting organization, distinguished by its status as the first entity to receive federal approval under the Clinical Laboratory Improvement Amendments (CLIA). With a legacy spanning over thirty-five years, the firm provides comprehensive accreditation services tailored to laboratories of varying scales. Beyond its core accreditation mandate, the company fosters professional development through the COLA Academy, ensuring that laboratory personnel remain at the forefront of industry standards and regulatory shifts. Their commitment to an educationally-focused methodology has resulted in a notable 98% customer satisfaction rate, cementing their reputation as a trusted partner for clinical excellence.
How much funding has COLA raised?
COLA has raised a total of $2.1M across 2 funding rounds:
Debt
$1M
Debt
$1.1M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.1M led by PPP
Key Investors in COLA
PPP
Public-Private Partnership
What's next for COLA?
With this major enterprise-level funding, COLA is well-positioned to scale its digital infrastructure and expand its educational offerings through the COLA Academy. The strategic allocation of this capital will likely focus on enhancing the efficiency of the accreditation process, integrating advanced regulatory tracking tools, and broadening the scope of their compliance services. As the healthcare sector faces increasing pressure for diagnostic accuracy and operational transparency, COLA's focus on physician-led oversight provides a competitive moat. The organization is expected to leverage these resources to further penetrate the market, ensuring that clinical laboratories remain compliant with evolving federal mandates while maintaining high standards of patient safety and diagnostic reliability.
See full COLA company page
